NasdaqGM · Drug Manufacturers - Specialty & Generic

Evolus (EOLS)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+78.8%

$15.00 average target

$8.39+0.04 (+0.5%)Latest market snapshot · Yahoo Finance

Market cap$554.2M

Cash$45.2M

Quarterly burn$3.6M

Pipeline assets3

Short float8.5%

Latest coverage

News & Press Releases

External sources

Aug 11, 2026

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to TradeZacks

Aug 6, 2026

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2Zacks

Aug 6, 2026

Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...GuruFocus.com

Continue with BioPharma ProUnlock 5 more recent stories and press releases.

Unlock Pro

Company profile

About Evolus

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.